Greg Zante - Mar 1, 2024 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Chief Financial Officer
Signature
/s/ Michael Morneau, as Attorney-in-Fact
Stock symbol
VKTX
Transactions as of
Mar 1, 2024
Transactions value $
-$1,712,325
Form type
4
Date filed
3/4/2024, 07:50 PM
Previous filing
Jan 4, 2024
Next filing
Mar 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Award $0 +31.7K +17.52% $0.00 212K Mar 1, 2024 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Tax liability -$1.71M -20.1K -9.46% $85.22* 192K Mar 1, 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on March 1, 2024 upon the achievement of a non-financial performance goal.
F2 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units.